Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
3.25M
-
Number of holders
-
16
-
Total 13F shares, excl. options
-
711K
-
Shares change
-
+226K
-
Total reported value, excl. options
-
$337K
-
Value change
-
+$106K
-
Number of buys
-
10
-
Number of sells
-
-6
-
Price
-
$0.47
Significant Holders of Enveric Biosciences, Inc. - Common Stock, $0.01 par value (ENVB) as of Q3 2024
20 filings reported holding ENVB - Enveric Biosciences, Inc. - Common Stock, $0.01 par value as of Q3 2024.
Enveric Biosciences, Inc. - Common Stock, $0.01 par value (ENVB) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 711K shares
of 3.25M outstanding shares and own 21.9% of the company stock.
Largest 10 shareholders include AdvisorShares Investments LLC (367K shares), GEODE CAPITAL MANAGEMENT, LLC (218K shares), TWO SIGMA SECURITIES, LLC (30.6K shares), Virtu Financial LLC (23.1K shares), VANGUARD GROUP INC (18.2K shares), Tower Research Capital LLC (TRC) (17.4K shares), TWO SIGMA INVESTMENTS, LP (13.4K shares), CITADEL ADVISORS LLC (12.8K shares), BlackRock, Inc. (9.01K shares), and UBS Group AG (730 shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.